The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. Teliso-V ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback